A Combination of Durvalumab-Tremelimumab with mFOLFOX6 Is Tolerable with Promising Activity in Patients with Microsatellite Stable Metastatic Colorectal Cancer
Findings from the MEDITREME study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1586 results
Efficacy and Safety of Elranatamab, BCMA-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
Findings from the registrational phase II MagnetisMM-3 study
FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA-mutated Metastatic Castration-Resistant Prostate Cancer
Evidence for efficacy is based on the results from the MAGNITUDE study
EMA Adopts a Positive Opinion for a New Indication for Pembrolizumab
New indication concerns the combination first-line treatment for locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma
First Prospective Description of Familial EGFR-mutated Lung Cancer
Findings from the INHERIT study
Low Incidence of Local Recurrence When Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer
Findings from the LUMINA study
Panitumumab Added to Infusional Fluorouracil Plus Leucovorin May Be a Reasonable Initial Treatment Option for Elderly Patients with RAS/BRAF wild-type mCRC
Findings from the PANDA study
FDA Approves Trifluridine and Tipiracil with Bevacizumab for Previously Treated Metastatic Colorectal Cancer
Evidence for efficacy is based on the results from the SUNLIGHT study
EMA Recommends Granting a Conditional Marketing Authorisation for Epcoritamab
It is indicated for the treatment of adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy
Long-Term Efficacy of Single-Agent Neoadjuvant/Adjuvant PD1 Blockade for Resectable Cutaneous Melanoma in Patients with a pCR
Findings from the longest follow-up of a neoadjuvant study in this setting
Zolbetuximab plus CAPOX Prolongs Survival in CLDN18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma
Findings from the GLOW study
A Positive Trend in OS Improvement Favours Atezolizumab Compared to Best Supportive Care in Stage II-IIIA Resected NSCLC, Primarily Driven by the PD-L1 TC ≥50% Subgroup
Findings from the IMpower010 study